A study published in JAMA Network Open August 11 suggests that, despite the growing use of imaging modalities like computed tomography and MRI, echocardiography remains the most popular method for imaging patients with heart failure.
Newly diagnosed HF patients with concomitant mitral regurgitation can expect more admissions, longer hospital stays and pricier medical bills than HF patients without MR, according to an analysis published in the American Journal of Cardiology.
Swiss drugmaker Novartis on July 29 announced its combo sacubitril/valsartan drug Entresto “narrowly missed” its primary endpoint in the Phase III PARAGON-HF study, throwing into question the future of a blockbuster drug.
The combination heart failure drug sacubitril/valsartan is well-covered under Medicare Part D plans, according to a recent analysis, but patient access to the medication remains limited by steep out-of-pocket costs than can exceed $1,600 annually.
Only half of the world’s countries offer cardiac rehabilitation programs, according to a recent survey, leaving some 18 million heart patients across the globe without access to therapy that could vastly improve their prognosis and quality of life.
Heart patients of a lower socioeconomic status are far more likely to participate in cardiac rehabilitation if they receive financial incentives to attend sessions, according to a study published in the July 1 edition of JACC: Heart Failure.